"The current challenge facing the life sciences R&D market is the sheer number of data generated and the ability to analyse"

A company previously affiliated with PerkinElmer, Inc., US-based Revvity, Inc was recently launched as an independent science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.

- Dr Manbeena Chawla

Revvity provides reagents, consumables, assays, instruments and software to customers in markets ranging from pharma and biotech, to diagnostic labs, academia and government agencies. During a detailed discussion with BioSpectrum, Shripad Joshi, President, India and South Asia at Revvity speaks at length about the company’s presence and growth plans in the Asia-Pacific (APAC) region. Edited excerpts:

What are the current offerings and key highlights of your product portfolio for the APAC countries?

Revvity is a visionary partner in developing technologies and solutions to help solve the world’s greatest health challenges and powering innovation from discovery to development, and diagnosis to cure. Our unified portfolio delivers complete solutions across translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Some of our most innovative solutions include the Honeycomb Single-Cell Platform and Organoid Platform derived from our collaboration with Honeycomb Biotechnologies. The Honeycomb HIVE is currently being used to isolate a patient’s cells before and after treatment and observe the impact a drug can have at the single-cell level. Our organoid platform combines our automation, flagship Opera Phenix Plus HighContent Imager and Celigo Cytometry Platform, allowing the generation of 3D organoids that mimic organs in the body. These innovations enable an endless possibility of applications for clinical and precision medicine in the near future.

In terms of new product launches, investments and partnerships in the APAC market, how promising is 2023?